(19)
(11) EP 2 852 588 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
10.01.2018 Bulletin 2018/02

(45) Mention of the grant of the patent:
29.11.2017 Bulletin 2017/48

(21) Application number: 13725443.9

(22) Date of filing: 22.05.2013
(51) International Patent Classification (IPC): 
A61K 31/506(2006.01)
A61K 31/4166(2006.01)
 A61K 31/4439(2006.01)
A61P 25/00(2006.01)
(86) International application number:
PCT/GB2013/051343
(87) International publication number:
WO 2013/175211 (28.11.2013 Gazette 2013/48)

(54)

HYDANTOIN DERIVATIVES AS KV3 INHIBITORS

HYDANTOINDERIVATE ALS KV3-INHIBITOREN

DÉRIVÉS D'HYDANTOÏNE EN TANT QU'INHIBITEURS DE KV3

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 22.05.2012 GB 201209013
06.06.2012 GB 201209986
13.12.2012 GB 201222528

(43) Date of publication of application:
01.04.2015 Bulletin 2015/14

(73) Proprietor: Autifony Therapeutics Limited
Hertfordshire SG1 2FX (GB)

(72) Inventor:
  • LARGE, Charles
    37135 Verona (IT)

(74) Representative: O'Kane, Jessica Ann 
Sagittarius IP Three Globeside Fieldhouse Lane
Marlow, Buckinghamshire SL7 1HZ
Marlow, Buckinghamshire SL7 1HZ (GB)


(56) References cited: : 
WO-A1-2011/069951
WO-A1-2012/168710
 WO-A1-2012/076877
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).